PE20080363A1 - Composicion farmaceutica que comprende ketorolaco y complejo b - Google Patents
Composicion farmaceutica que comprende ketorolaco y complejo bInfo
- Publication number
- PE20080363A1 PE20080363A1 PE2007000424A PE2007000424A PE20080363A1 PE 20080363 A1 PE20080363 A1 PE 20080363A1 PE 2007000424 A PE2007000424 A PE 2007000424A PE 2007000424 A PE2007000424 A PE 2007000424A PE 20080363 A1 PE20080363 A1 PE 20080363A1
- Authority
- PE
- Peru
- Prior art keywords
- ketorolaco
- complex
- vitamin
- pharmaceutical composition
- composition including
- Prior art date
Links
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 abstract 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
- 229960002104 cyanocobalamin Drugs 0.000 abstract 1
- 235000000639 cyanocobalamin Nutrition 0.000 abstract 1
- 239000011666 cyanocobalamin Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229960004752 ketorolac Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 abstract 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 abstract 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 abstract 1
- 229960000344 thiamine hydrochloride Drugs 0.000 abstract 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 abstract 1
- 239000011747 thiamine hydrochloride Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE A) UNA SAL DE KETOROLACO TAL COMO TROMETAMINA EN UNA CANTIDAD QUE VA DESDE 2 MG HASTA 30 MG Y B) COMPLEJO B QUE COMPRENDE VITAMINA B1 (CLORHIDRATO O MONOHIDRATO DE TIAMINA) EN UNA CANTIDAD QUE VA DESDE 15 MG HASTA 250 MG Y/O VITAMINA B6 (CLORHIDRATO DE PIRIDOXINA) QUE VA DESDE 15 MG HASTA 250 MG Y/O VITAMINA B12 (CIANOCOBALAMINA) QUE VA DESDE 0.1 MG A 10 MG. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA COMBINACION, DE ADMINISTRACION ORAL O PARENTERAL ADECUADA PARA ADMINISTRACION INTRAMUSCULAR O INTRAVENOSA Y UN PROCEDIMIENTO DE PREPARACION; OBTENIENDOSE ASI UNA COMPOSICION ESTABLE QUE DISMINUYE LOS EFECTOS ADVERSOS DEL KETOROLACO SIENDO UTIL EN EL TRATAMIENTO DE DOLOR SEVERO Y NEURALGIAS DE DIVERSA LOCALIZACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA/A/2006/004020A MXPA06004020A (es) | 2006-04-10 | Composicion farmaceutica que comprende un analgesico y vitaminas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080363A1 true PE20080363A1 (es) | 2008-05-25 |
Family
ID=38580737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000424A PE20080363A1 (es) | 2006-04-10 | 2007-04-09 | Composicion farmaceutica que comprende ketorolaco y complejo b |
| PE2011001166A PE20120122A1 (es) | 2006-04-10 | 2007-04-09 | Composicion farmaceutica que comprende un analgesico y vitaminas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001166A PE20120122A1 (es) | 2006-04-10 | 2007-04-09 | Composicion farmaceutica que comprende un analgesico y vitaminas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090227534A1 (es) |
| EP (1) | EP2008655B1 (es) |
| JP (1) | JP5244089B2 (es) |
| AR (1) | AR060394A1 (es) |
| BR (1) | BRPI0709967A2 (es) |
| CA (1) | CA2649194C (es) |
| CO (1) | CO6331430A2 (es) |
| CR (1) | CR10360A (es) |
| DO (1) | DOP2007000055A (es) |
| EC (1) | ECSP088801A (es) |
| ES (1) | ES2428342T3 (es) |
| GT (1) | GT200800208A (es) |
| HN (1) | HN2008001531A (es) |
| PE (2) | PE20080363A1 (es) |
| PL (1) | PL2008655T3 (es) |
| WO (1) | WO2007116287A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008003230A (es) * | 2008-03-07 | 2009-09-07 | Senosiain S A De C V Lab | Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b. |
| SI2616064T1 (sl) | 2010-10-21 | 2019-12-31 | Rtu Pharmaceuticals Llc | Pripravki ketorolaka, pripravljeni za uporabo |
| AU2013201465B2 (en) * | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| TWI809304B (zh) | 2014-12-01 | 2023-07-21 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2823167A (en) * | 1955-03-29 | 1958-02-11 | Vitarine Co Inc | Stable vitamin b12-containing solution |
| FR4492M (es) * | 1965-07-07 | 1966-10-10 | ||
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
| US6051587A (en) | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| US20030191187A1 (en) * | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| MXPA02010828A (es) | 2002-11-04 | 2004-07-16 | Leopoldo Espinosa Abdala | Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor. |
-
2007
- 2007-03-22 DO DO2007000055A patent/DOP2007000055A/es unknown
- 2007-04-09 PE PE2007000424A patent/PE20080363A1/es not_active Application Discontinuation
- 2007-04-09 PE PE2011001166A patent/PE20120122A1/es active IP Right Grant
- 2007-04-10 US US12/226,219 patent/US20090227534A1/en not_active Abandoned
- 2007-04-10 EP EP07734226.9A patent/EP2008655B1/en not_active Not-in-force
- 2007-04-10 BR BRPI0709967-3A patent/BRPI0709967A2/pt not_active IP Right Cessation
- 2007-04-10 PL PL07734226T patent/PL2008655T3/pl unknown
- 2007-04-10 CA CA2649194A patent/CA2649194C/en not_active Expired - Fee Related
- 2007-04-10 ES ES07734226T patent/ES2428342T3/es active Active
- 2007-04-10 JP JP2009504843A patent/JP5244089B2/ja not_active Expired - Fee Related
- 2007-04-10 WO PCT/IB2007/000907 patent/WO2007116287A1/es not_active Ceased
- 2007-04-10 AR ARP070101491A patent/AR060394A1/es not_active Application Discontinuation
-
2008
- 2008-10-08 EC EC2008008801A patent/ECSP088801A/es unknown
- 2008-10-09 GT GT200800208A patent/GT200800208A/es unknown
- 2008-10-10 CR CR10360A patent/CR10360A/es not_active Application Discontinuation
- 2008-10-10 CO CO08108827A patent/CO6331430A2/es not_active Application Discontinuation
- 2008-10-10 HN HN2008001531A patent/HN2008001531A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2649194A1 (en) | 2007-10-18 |
| DOP2007000055A (es) | 2007-10-31 |
| GT200800208A (es) | 2010-03-18 |
| EP2008655A1 (en) | 2008-12-31 |
| ECSP088801A (es) | 2009-01-30 |
| BRPI0709967A2 (pt) | 2011-08-02 |
| CR10360A (es) | 2009-02-20 |
| WO2007116287A1 (es) | 2007-10-18 |
| CO6331430A2 (es) | 2011-10-20 |
| HN2008001531A (es) | 2011-07-12 |
| AR060394A1 (es) | 2008-06-11 |
| PL2008655T3 (pl) | 2013-11-29 |
| JP2009533413A (ja) | 2009-09-17 |
| CA2649194C (en) | 2014-12-30 |
| PE20120122A1 (es) | 2012-03-09 |
| JP5244089B2 (ja) | 2013-07-24 |
| ES2428342T3 (es) | 2013-11-07 |
| EP2008655B1 (en) | 2013-06-26 |
| US20090227534A1 (en) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200810125B (en) | Pharmaceutical combination comprising 3- (3-dimethy-lamin0-1-ethyl-2-methyl-pr0pyl)-phenol and an NSAID | |
| AR062760A1 (es) | Administracion de inhibidores de dipeptidilpetidasa | |
| PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
| CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| CL2008002999A1 (es) | Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon. | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| BR112012009857A2 (pt) | composições farmacêuticas sólidas contendo um inibidor de integrase | |
| PE20080363A1 (es) | Composicion farmaceutica que comprende ketorolaco y complejo b | |
| ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| PE20170426A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| CL2007000947A1 (es) | Formas cristalinas de las sales de esilato, oxalato, mesilato y maleato de 8-[[1-(3,5-bis-(trifluorometil)fenil)-etoxi]-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; composicion farmaceutica; y uso en la preparacion de un medicamento par el tratamiento y/o prevencion de emesis y/o nausea. | |
| MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
| AR054442A1 (es) | Formas de dosificacion, composiciones farmaceuticas y metodos para el suministro sub-tenon | |
| GT200500364A (es) | Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10 | |
| CL2008002485A1 (es) | Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para el tratamiento de la endometriosis con reduccion de los efectos colaterales terapeuticos; procedimiento de preparacion de una composicion farmaceutica que comprende a dichos compuestos. | |
| AR072871A1 (es) | Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |